Literature DB >> 22185816

Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.

Lay Kek Teh1, Leif Bertilsson.   

Abstract

CYP2D6 has received intense attention since the beginning of the pharmacogenetic era in the 1970s. This is because of its involvement in the metabolism of more than 25% of the marketed drugs, the large geographical and inter-ethnic differences in the genetic polymorphism and possible drug-induced toxicity. Many interesting reviews have been published on CYP2D6 and this review aims to reinstate the importance of the genetic polymorphism of CYP2D6 in different populations as well as some clinical implications and important drug interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22185816     DOI: 10.2133/dmpk.dmpk-11-rv-121

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  63 in total

1.  Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.

Authors:  T M Dodgen; C De J Labuschagne; A van Schalkwyk; F E Steffens; A Gaedigk; A D Cromarty; M Alessandrini; M S Pepper
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

Review 2.  Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.

Authors:  Timothy Eley; Tushar Garimella; Wenying Li; Richard J Bertz
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

3.  Investigation of CYP2D6 Gene Polymorphisms in Turkish Population.

Authors:  Bayram Taskin; Ferda E Percin; Mehmet Ali Ergun
Journal:  Psychopharmacol Bull       Date:  2016-03-01

Review 4.  Application of pharmacogenetics in clinical practice: problems and solutions.

Authors:  Andrius Baskys
Journal:  J Neural Transm (Vienna)       Date:  2018-06-19       Impact factor: 3.575

5.  Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects.

Authors:  Eui Hyun Jung; Choong-Min Lee; Ji-Yeong Byeon; Hyo-Bin Shin; Kyung-Yul Oh; Chang-Keun Cho; Chang Woo Lim; Choon-Gon Jang; Seok-Yong Lee; Yun Jeong Lee
Journal:  Arch Pharm Res       Date:  2020-07-13       Impact factor: 4.946

6.  Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.

Authors:  Hiroyuki Kobayashi; Kazuhiro Sato; Takenori Niioka; Masahide Takeda; Yuji Okuda; Mariko Asano; Hiroshi Ito; Masatomo Miura
Journal:  Med Oncol       Date:  2016-05-06       Impact factor: 3.064

7.  Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.

Authors:  Michael A Brodney; Elizabeth M Beck; Christopher R Butler; Gabriela Barreiro; Eric F Johnson; David Riddell; Kevin Parris; Charles E Nolan; Ying Fan; Kevin Atchison; Cathleen Gonzales; Ashley E Robshaw; Shawn D Doran; Mark W Bundesmann; Leanne Buzon; Jason Dutra; Kevin Henegar; Erik LaChapelle; Xinjun Hou; Bruce N Rogers; Jayvardhan Pandit; Ricardo Lira; Luis Martinez-Alsina; Peter Mikochik; John C Murray; Kevin Ogilvie; Loren Price; Subas M Sakya; Aijia Yu; Yong Zhang; Brian T O'Neill
Journal:  J Med Chem       Date:  2015-04-01       Impact factor: 7.446

Review 8.  Personalized medicine: Genetic risk prediction of drug response.

Authors:  Ge Zhang; Daniel W Nebert
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

9.  Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers.

Authors:  Norliza Mat Ariffin; Farida Islahudin; Endang Kumolosasi; Mohd Makmor-Bakry
Journal:  Parasitol Res       Date:  2019-01-31       Impact factor: 2.289

Review 10.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.